ERBB2 and cancer: Patients with HR+ subtype cancer could receive endocrine therapy in addition to surgery and radiation treatment; patients with HER2+ subtype cancer could receive additional targeted treatment with monoclonal antibodies; patients with TNBC currently have no available targeted treatment (48).